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Background. Injection drug users (IDUs) who successfully clear hepatitis C virus (HCV) have a reduced risk of
developing chronic reinfection, despite their continuing exposure to the virus. To identify immunological correlates
for this apparent protection, we studied HCV-specific immune responses in long-term IDUs (duration,10 years).
Methods. HCV-specific T cell responses were assessed in proliferation, enzyme-linked immunospot (ELISPOT),
interferon (IFN)– secretion, and cytotoxicity assays, whereas HCV-specific antibodies were assessed in enzyme
immunoassays (EIAs), chemiluminescent assays, and in vitro neutralization assays.
Results. HCV-specific T cell proliferation and IFN- production were more common in nonviremic EIA-
positive IDUs (16 [94%] of 17 IDUs) than in viremic EIA-positive IDUs (9 [45%] of 20 IDUs) (P  .003). They were
also noted in 16 (62%) of 26 nonviremic EIA-negative IDUs. In contrast, 19 (90%) of 21 viremic IDUs displayed
neutralizing antibodies (nAbs), compared with 9 (56%) of 16 nonviremic EIA-positive IDUs (P  .04) and 0 of 24
nonviremic EIA-negative IDUs. Nonviremic IDUs with nAbs were older (P  .0115) than those without nAbs, but
these groups did not differ in terms of either injection drug use duration or HCV-specific T cell responses.
Conclusion. The reduced risk of HCV persistence in IDUs previously recovered from HCV infection correlated
with T cell responses, and prolonged antigenic stimulation appears to be required to maintain humoral responses.
Injection drug users (IDUs) constitute the largest group of
HCV-infected people in the United States and account for
42% of new infections [1]. After 10 years of injection drug
use, 90% of IDUs test anti-HCV positive by means of
standard EIA [2]; of these IDUs, 80% are persistently in-
fected with HCV [2, 3]. The most common mode of HCV
transmission is multiperson use of contaminated syringes
and other injection-related paraphernalia [4].
More than 40,000 IDUs live in the San Francisco Bay
area [5]. From 1986 through 2005, the Urban Health
Study (UHS) recruited active IDUs from street settings
in inner-city San Francisco Bay area neighborhoods,
counseled them regarding reducing the risk of infection,
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tested them for HIV antibodies, and referred them to appropri-
ate medical and social services [6 – 8]. Prospective, semiannual
sampling revealed that the prevalence of HCV antibody in-
creased in association with the duration of injection drug use [2,
3, 9, 10], which likely reflects an effect of cumulative exposure.
Interestingly, however, the incidence of new HCV infections, as
measured by seroconversion, decreased in association with
longer durations of injection drug use. This reduction in the
incidence of HCV infection did not appear to be a chance phe-
nomenon and was independent of risk behavior (B.R.E., unpub-
lished data), suggesting that seronegative IDUs with a long du-
ration of HCV exposure may have some degree of innate or
acquired immunity.
In this context, 2 recent epidemiological studies demon-
strated that IDUs who successfully cleared HCV in the past have
a reduced risk of developing persistent HCV viremia, despite
continued injection drug use and continued exposure to HCV
[11, 12]. Subjects who had cleared a past HCV infection were 2
times [11] and 4 times [12] less likely to develop persistent HCV
infection than were subjects without evidence of past HCV ex-
posure. To identify potential immunological correlates of im-
mune protection, we studied the cellular and humoral immune
responses of a subgroup of IDUs in the UHS who reported in-
jection drug use of10 years’ duration.
SUBJECTS AND METHODS
Study Population
The UHS was a serial, cross-sectional study that recruited IDUs in
street settings in 6 inner-city San Francisco Bay Area neighborhoods
to investigate factors affecting the health of these IDUs and to de-
velop and evaluate interventions and policies to improve their
health. A new cross-section of IDUs was recruited every 6 months,
by use of targeted sampling methods [6, 13]. Eligibility for the study
was based on the subjects having injected drugs in the past 30 days.
After participating in the study once, IDUs were eligible to partici-
pate again as often as every 6 months, but they were not specifically
recruited in follow-up [7, 13].
The research presented in the current article was conducted
using epidemiological data for and blood samples obtained from
UHS participants who had injected drugs for10 years and who
fulfilled one of the following criteria: they were (1) viremic, as
determined by reverse-transcription polymerase chain reac-
tion (RT-PCR) (sensitivity, 50 copies/mL) [14], and anti-HCV
positive, as determined by 2 consecutive standard EIAs (HCV
Version 3.0 ELISA Test System; Ortho-Clinical Diagnostics)
performed6 months apart; (2) nonviremic, as determined by
RT-PCR, and EIA positive, as determined by 2 consecutive tests
performed6 months apart; or (3) nonviremic, as determined
by RT-PCR, and EIA negative, as determined from results for 2
consecutive samples assessed 6 months apart by use of the
HCV Version 3.0 ELISA Test System. HCV RNA was quanti-
tated using the Cobas HCV TaqMan assay (Roche). The study
was limited to the first 66 HIV-negative IDUs who fulfilled these
criteria and were willing to participate. Twenty-nine healthy,
HCV RNA–negative, HCV EIA–negative blood donors at the
National Institutes of Health (NIH) who did not have any his-
tory of hepatitis served as controls for the immunological assays.
All subjects provided written, informed consent for research
testing, which was approved by the Committee on Human Sub-
jects Research at the University of California, San Francisco, and
the institutional review board of the National Cancer Institute,
NIH. Participants were advised about reducing their risk behav-
iors; given pretest and posttest HIV, HBV, and HCV counseling;
and referred to medical and social services, as needed. Risk be-
haviors and demographic data were collected by trained inter-
viewers who used a detailed, standardized questionnaire admin-
istered at community-based field sites.
Synthetic Proteins and Peptides
Recombinant HCV core, NS3, helicase, NS4, NS5A, and NS5B
proteins (genotype 1, the predominant HCV genotype of the
UHS participants) were purchased from Mikrogen. Fifteen-mer
peptides that were synthesized according to the HCV genotype 1
H77 sequence and were overlapping by 10 amino acids (Mimo-
topes) were pooled to generate 1 HCV core pool (38 peptides), 3
HCV NS3 pools (each with 42 peptides), 1 HCV NS4A pool (12
peptides), and 2 HCV NS4B pools (each with 26 peptides). The
HLA-A2–restricted CD8T cell epitopes NS31073–1081 CVNGVC-
WTV, Core35– 44 YLLPRRGPRL, and Core131–140 ADLMGYIPLV
were synthesized at the Center for Biologics Evaluation and Re-
search of the US Food and Drug Administration (FDA).
Proliferation Assays
Blood samples were encoded so that the subject’s identity was
not revealed and obtained in acid citrate dextrose–anticoagu-
lated tubes at community-based field sites and were shipped to
the NIH overnight at ambient temperature. Peripheral blood
mononuclear cells (PBMCs) were separated from 50 mL of
blood, and proliferation assays were performed as described
elsewhere [14]. Results were expressed as the stimulation index
(counts per minute in the presence of antigen divided by counts
per minute in the absence of antigen). The cutoff value for a
significant response was a stimulation index of 3, which was
equivalent to the mean plus 2 SDs proliferative response of 29
healthy, anti-HCV–negative NIH blood donors.
IFN- Enzyme-Linked Immunospot (ELISPOT) and Cytokine
Secretion Assays
Duplicate cultures of 3  105 freshly isolated PBMCs were stim-
ulated with 1 g/mL HCV protein, 1 g/mL each HCV peptide
in the respective pool, or 1 g/mL phytohemagglutinin (PHA;
Murex Biotech) in RPMI 1640 containing 5% serum from do-
nors with blood group AB and 2 mmol/L L-glutamine [15]. The
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number of specific spots (i.e., the number of spots in the pres-
ence of antigen minus the number of spots in the absence of
antigen) was determined using a KS ELISPOT Reader (Zeiss). A
positive response was defined as a response greater than the
mean plus 2 SDs of the IFN- response of healthy NIH blood
donors without a history of HCV infection. The protein-specific
cutoff values were 7.8 spots (for HCV core), 21 spots (for NS3),
5 spots (for NS4A), and 13.4 spots (for NS4B).
IFN- cytokine secretion assays were performed according to
the instructions of the manufacturer (Miltenyi Biotec), with the
use of 2  106 PBMCs stimulated for 3 h with or without the
respective peptide pool, or with 1 g/mL PHA in 500 L of
RPMI 1640 (Cellgro) supplemented with 10% FBS, 2 mmol/L
L-glutamine, 100 g/mL streptomycin, 100 U/mL penicillin.
Samples were analyzed on a FACScalibur flow cytometer with
CellQuest software (version 3.3; Becton Dickinson).
HLA Typing, Generation of HLA-A2–Restricted T Cell Lines,
and Cytotoxicity Assay
HLA class I typing was performed by amplifying genomic
DNA according to protocols recommended by the 13th Inter-
national Histocompatibility Workshop [16]. Alleles were as-
signed according to the reaction patterns of the sequence-
specific oligonucleotides probes, and ambiguities were
resolved by sequencing.
PBMCs from HLA-A2–positive, exposed, uninfected subjects
were stimulated with epitopes NS31073–1081 CVNGVCWTV,
Core35– 44 YLLPRRGPRL, and Core131–140 ADLMGYIPLV, to gen-
erate T cell lines [14]. Cytotoxicity was assessed in a standard
cytotoxicity assay using 51Cr-labeled, peptide-pulsed JY–
Epstein-Barr virus (EBV) cells as target cells [14]. Spontaneous
release was15% of maximum release.
Table 1. Characteristics of the injection drug users studied.
Characteristic
Viremic
EIA-positive
subjectsa
(n  21)
Nonviremic subjects
P d
EIA positiveb
(n  17)
EIA negativec
(n  28)
Age, median (IQR), years 51 (48.5–55) 51 (48.5–53.5) 44.5 (38–50) .0016e; .0011f
Duration of IDU, median (IQR), years 34 (29.5–35.5) 32 (29–34.5) 18 (12.5–28) .00011e; .0001f
Sex, no. (%) of male subjects 20 (95) 10 (59) 24 (86)
Race
White 7 (33) 7 (41) 12 (43)
Black 14 (67) 7 (41) 15 (54)
Other 0 3 (18) 1 (4)
Needle sharingg
Yes 2 (10) 5 (29) 4 (14)
No 19 (90) 11 (65) 24 (86)
Unknown 0 1 0
Frequency of IDU
In the past month
Median (IQR) 8 (0–44) 1 (0–60) 12 (0–34.5)
Unknown 0 0 1
In the past 6 months
Median (IQR) 48 (3–371.5) 323 (36–393) 77 (36.5–259)
Unknown 0 1 0
No. of sex partners,g median (IQR) 1 (0–1) 1 (0.5–1) 2 (1–4)
Type of sexual contact
Homosexual 0 0 1 (4)
Bisexual 2 (10) 0 1 (4)
Heterosexual 18 (86) 17 (100) 23 (82)
Unknown 1 0 3
Received money or drugs for sex 5 (24) 4 (24) 10 (36)
NOTE. Data are no. or no. (%) of subjects, unless otherwise indicated. IDU, injection drug use; IQR, interquartile range;
a HCV RNA positive by reverse-transcriptase polymerase chain reaction (RT-PCR) and HCV antibody positive by EIA assay.
b HCV RNA negative by RT-PCR and HCV antibody positive by EIA assay.
c HCV RNA negative by RT-PCR and HCV antibody negative by EIA assay.
d By Mann-Whitney U test; only statistically significant findings with a 2-sided P value of .05 are indicated.
e Viremic EIA-positive subjects vs. nonviremic EIA-negative subjects.
f Nonviremic EIA-positive subjects vs. nonviremic EIA-negative subjects.
g In the past 6 months.
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Analysis of Humoral Immune Responses
Whereas the HCV Version 3.0 ELISA Test System (Ortho-Clinical
Diagnostics), along with HCV RNA testing, was used to classify
subjects as viremic EIA-positive, nonviremic EIA-positive, and
nonviremic EIA-negative groups (see above), 2 assays were used to
further characterize the antibody responses of each group.
Neutralizing antibodies (nAbs). Plasma samples were
screened at a final dilution of 1/100 for their ability to neutralize
infection of human hepatoma Huh-7.5 cells by retroviral
pseudotypes bearing either HCV genotype 1a (H77) glycopro-
teins or, as a specificity control, murine leukemia virus glycopro-
teins [17]. Heat-inactivated samples were mixed with virus at
their appropriate dilution in 3% fetal bovine serum/DMEM plus
4 g/mL polybrene and were incubated for 1 h at 37°C. This
virus-plasma mix was allowed to infect Huh-7.5 cells seeded in
96-well plates (8  103 cells/well) for 6 h at 37°C. Unbound
virus was removed, and the infected cells were incubated for a
total of 72 h. Cells were lysed with cell buffer (Promega) and
tested for luciferase activity [17]. The percentage of neutraliza-
tion was determined by comparing pseudotype infectivity in the
presence of test plasma in relation to infection in the presence of
control plasma (without HCV antibodies) at the same dilution.
Plasma samples that inhibited infection by50% were consid-
ered to be neutralizing.
Anti-HCV chemiluminescent assay. Unlike traditional
EIAs, the FDA-approved Vitros Immunodiagnostic Anti-HCV
Assay (ECi; Ortho-Clinical Diagnostics) has a very broad, dy-
namic range for the detection of antibodies to recombinant
HCV core, NS3, NS4, and NS5 antigens, which, in part, is due to
the fact that enhanced chemiluminescence is the positive signal
generator [18, 19]. Samples with a signal/cutoff (S/CO) ratio of
1.00 were considered to have a positive result, and samples
with an S/CO of0.90 were considered to have a negative result.
Samples with an S/CO ratio of0.90 and1.00 were retested in
duplicate on the basis of the manufacturer’s recommendations.
Statistical Analysis
Fisher’s exact test (2-tailed) was used to compare the frequency
of immune responses in the 3 different IDU groups. Nonpara-
metric Mann-Whitney tests and unpaired Student’s t tests were
used to compare subject age and the duration of injection drug
use, as well as the strength of responses in different IDU groups.
Stratified analysis and logistic regression models were used to
compare the HCV-specific immune responses in HCV-infected
subjects with those in HCV-recovered subjects while controlling
for age (50 years vs.50 years), duration of injection drug use,
race (black vs. white or other), and sex. The odds ratio (OR)
combined over strata was estimated using exact methods with a
mid-P– corrected confidence interval. Analyses were performed
using Prism software (version 3; GraphPad) and StatXact soft-
ware (version 7; Cytel). A 2-sidedP value of.05 was considered
to be statistically significant.
RESULTS
On the basis of 2 consecutive tests performed6 months apart, 66
UHS participants were stratified into HCV-viremic EIA-positive,
Table 2. Immune responses of viremic EIA-positive and nonviremic EIA-positive in-
jection drug users, as stratified by age and race.
Response
Viremic
EIA-positive
subjects,
n/N (%)a
Nonviremic
EIA-positive
subjects
n/N (%)a OR (95% CI) Exact P
T cell proliferation
All subjects 8/21 (38) 13/17 (76) 5.28 (1.06–29.2) .04
Adjustedb for age and race 4.76 (1.04–27.2) .07
T cell IFN- production
All subjects 3/20c (15) 13/17 (76) 18.4 (2.84–138) .0004
Adjustedb for age and race 37.4 (4.79–981) .0001
Any T cell responsed
All subjects 9/20c (45) 16/17 (94) 19.6 (2.04–893) .003
Adjustedb for age and race 19.9 (2.46–550) .002
nAbs
All subjects 19/21 (90) 9/16c (56) 0.13 (0.01–0.95) .04
Adjustedb for age and race 0.07 (0.002–0.60) .01
NOTE. Statistical analyses were performed using StatXact software (version 7; Cytel). CI, confidence
interval; IFN, interferon; nAbs, neutralizing antibodies; OR, odds ratio.
a No. of responders/total no. of subjects (% of subjects who were responders).
b OR combined over strata was estimated using exact methods with a mid-P–corrected CI. Analysis
controlled for sex produced similar results.
c One subject was not tested.
d Proliferation or IFN-.
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nonviremic EIA-positive, and nonviremic EIA-negative groups. Vi-
remic participants had a median HCV titer of 3.39  106 IU/mL
(interquartile range [IQR], 1.34  106–1.17  107), and the
majority was infected with HCV genotype 1. Viremic EIA-
positive participants were comparable to nonviremic EIA-
positive participants, in terms of age and duration of injection
drug use (table 1). In contrast, nonviremic EIA-negative IDUs
were, on average, 6.5 years younger (P  .0011) than other
UHS participants and reported a 15-year shorter duration of
injection drug use (P  .0001). Most viremic EIA-positive
IDUs were male and black, consistent with the overall trend ob-
served among UHS participants [3]. Approximately two-thirds
injected drugs less than once a day, and they did not share syringes.
Most were heterosexual and had few sex partners (table 1).
HCV-specific T cell proliferation in viremic EIA-positive
and nonviremic EIA-positive IDUs. HCV-specific T cells
were first evaluated for their proliferative capacity in response to
HCV core, NS3, NS4, NS5A, and NS5B proteins. HCV-specific T
cell proliferation was more common among nonviremic EIA-
positive IDUs (76%) than among viremic EIA-positive IDUs
(38%) (OR, 5.28; P  .04). Analyses that controlled for the ef-
fects of age, race, and sex produced consistent results (table 2).
Compared with viremic EIA-positive IDUs, nonviremic EIA-
positive IDUs had a higher mean stimulation index (25.4 vs.
10.5; P  .01) (figure 1A) and were more likely to have a stim-
ulation index value10 (figure 1B). Among the individual HCV
proteins, the greatest difference in the strength of the response
between groups was observed for the HCV core protein and the
Figure 1. Hepatitis C virus (HCV)–specific proliferative T cell response to recombinant HCV proteins. A–C, Strength of the HCV-specific proliferative
T cell response to all (A and B) or individual HCV proteins (C). The mean (1 SD) of the antigen-specific response is indicated for viremic EIA–positive
subjects and nonviremic EIA-positive subjects, respectively. D, Response pattern of individual subjects. The stimulation index indicates proliferation in
the presence of antigen relative to proliferation in the absence of antigen. Hatched bars denote positive responses (defined as responses greater than
the mean stimulation index [2 SDs] of the response of healthy blood donors). C, HCV core protein; 3, HCV NS3 protein; H, HCV helicase protein; 4,
HCV NS4 protein; 5A, HCV NS5A protein; 5B, HCV NS5A protein; Pos., positive; SI, stimulation index.
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nonstructural HCV proteins NS3 and NS5B (figure 1C and 1D).
The differential response to HCV helicase, which is part of the
NS3 protein, confirmed the NS3-specific results (mean stimula-
tion index, 7.1 vs. 1.4; P  .0008) (figure 1C).
IFN- production of HCV-specific T cells in viremic EIA-
positive IDUs and in nonviremic EIA-positive IDUs. To
comprehensively analyze the IFN- response of both CD4 and
CD8T cells in the context of the HLA haplotype of each subject,
we performed ex vivo ELISPOT assays with pools of overlapping
HCV peptides (figure 2). Consistent with the results of the pro-
liferation assays, HCV-specific IFN- responses were more
common in nonviremic EIA-positive IDUs (13 [76%] of 17
IDUs) than in viremic EIA-positive IDUs (3 [15%] of 23 IDUs)
(OR, 18.4;P  .0004) (table 2), and this result was similar when
adjusted for age, race, and sex. Moreover, nonviremic EIA-
positive IDUs displayed a higher mean frequency of IFN-–
producing T cells in response to all tested HCV peptides (74.8
IFN-–producing cells/300,000 PBMCs) than did viremic EIA-
positive IDUs (19.3 IFN-–producing cells/300,000 PBMCs)
(P  .001) (figure 2A). When peptide pools of individual
HCV proteins were considered, the greatest differences be-
tween the nonviremic EIA-positive group and the viremic EIA-
Figure 2. T cell–mediated interferon (IFN)– response to pools of overlapping hepatitis C virus (HCV) peptides. A and B, Frequency of HCV-specific
IFN-–producing T cells in response to all tested pools of HCV peptides (A) and to peptide pools corresponding to individual HCV antigens (B). C,
Response pattern of individual subjects. Positive responses (hatched bars) were defined as responses greater than the mean stimulation index (2 SDs)
of the response of healthy blood donors. HCV-specific IFN-–producing T cells were detected in 3 of 20 viremic EIA-positive injection drug users (left
panels, note that subject V-14 was not tested) and in 13 of 17 nonviremic EIA-positive injection drug users (right panels). C, HCV core peptide pool;
3, HCV NS3 peptide pool; 4A, HCV NS4A peptide pool; 4B, HCV NS4A peptide pool. Peptides covering helicase were included in the pool of
HCV-NS3–specific peptides, because helicase is a part of NS3. ND, not done; Pos., positive.
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positive group were observed for HCV core peptides (15.2 vs. 2.8
HCV core–specific IFN-–producing cells/300,000 PBMCs;
P  .0069) and HCV NS3 peptides (44.7 vs. 5.6 HCV NS3-
specific IFN-–producing cells/300,000 PBMCs; P  .0015)
(figure 2B). These were the same antigens that yielded the great-
est differential response in the proliferation assay (figure 2C).
Moreover, most subjects with IFN- responses also displayed
proliferative responses (subjects P-3 to P-10, P-12, and P-14 and
subjects V-15 and V-16, respectively) (figure 1D and figure 2C).
Combining the data for T cell proliferation and IFN- pro-
duction, we found that evidence of any T cell response to HCV
was more common among nonviremic EIA-positive IDUs
(94%) than among viremic EIA-positive IDUs (45%) (OR, 19.6;
P  .003) (table 2). Analyses that controlled for the effects of
age, race, and sex produced consistent results.
HCV-specific nAbs in viremic EIA-positive and in nonvire-
mic EIA-positive IDUs. Whereas antibodies to structural and
nonstructural proteins of HCV, as detected in standard EIAs,
have been the standard diagnostic criteria for current or past
HCV infection for nearly 2 decades [20] and were used in the
present study to classify the subject groups, 2 recent assays were
used to further characterize the humoral immune response.
HCV pseudoparticles were used to assess in vitro antibody-
mediated inhibition of virus cell entry [17, 21, 22]. nAbs were
detected in 19 (90%) of 21 viremic EIA-positive subjects, com-
pared with 9 (56%) of 16 nonviremic EIA-positive subjects (OR,
0.130; P  .04) (table 2). Whereas the majority (11 [58%] of 19)
of viremic EIA-positive subjects with nAbs displayed a very high
nAB titer (9000), only 3 nonviremic EIA-positive subjects had
a titer of9000, and the average titer for the remaining 6 recov-
ered subjects with nAbs was 2000. Interestingly, nonviremic
EIA-positive subjects with nAb responses also had stronger an-
tibody responses to core, NS3, NS4, and NS5, as determined in
the anti-HCV chemiluminescent assay (median ECi score, 30.5
vs. 15;P  .0093), and were slightly older than nonviremic EIA-
positive subjects without nAb responses (median age, 53 years
vs. 50 years; P  .0115) (table 3). However, both subgroups
were relatively small and did not significantly differ in terms of
duration of injection drug use, frequency of injection drug use,
or prevalence or strength of HCV-specific T cell responses (table 3).
HCV-specific immune responses of nonviremic EIA-negative
IDUs. HCV-specific T cell proliferation was detectable in 13
(46%) of 28 [23] nonviremic EIA-negative IDUs (figure 3A). Six of
these subjects also displayed IFN- responses to overlapping HCV
peptides (figure 3B), which were mostly mediated by CD8 T cells
(figure 3C). As an independent confirmation of these ex vivo re-
sponses, we expanded HCV-specific CD8 T cells in vitro from
PBMCs and established T cell lines. As shown in figure 3D, repre-
sentative CD8 T cell lines from nonviremic EIA-negative IDUs
exhibited cytotoxic effector function against HLA-matched,
peptide-pulsed EBV B cell lines.
Overall, the response pattern varied widely among individual
subjects. Whereas subjects N-18 to N-20 displayed both prolif-
erative and IFN- responses, subjects N-1, N-4, N-6, N-8, N-13,
N-21, and N-21 to N-25 tested positive solely in T cell prolifer-
ation assays, and subjects N-26 to N-28 tested positive solely in T
Table 3. Comparison of nonviremic EIA-positive injection drug users with or without in vitro neutralizing
antibodies (nAbs).
Characteristic
Nonviremic EIA-positive IDUs
Pa
With nAbs
(n  9)
Without nAbs
(n  7)
Age, median (IQR), years 53 (51.0–54.5) 50 (45.0–51.0) .0115
Duration of IDU, median (IQR), years 32 (31.5–37.0) 30 (24.0–34.0) NS
Frequency of IDU, median (IQR)
In the past month 1 (0–65) 1 (0–87.5)b NS
In the past 6 months 355 (54–391)c 150 (12.5–830) NS
No. of sex partners, median (IQR) 1 (0–65) 1 (0–4.5) NS
HCV Abs, median (IQR), ECi score 30.5 (28.5–30.8)c 15 (3.6–29.8) .0093
HCV-specific T cell proliferation
No. (%) of subjects 8 (89) 4 (57) NS
Response strength, median (IQR), SI 13.4 (9.5–30.2) 11.8 (5.1–72.2) NS
HCV-specific T cell IFN- production
Subjects with T cell IFN- production, no. (%) 6 (67) 6 (86) NS
Response strength, median (IQR), ELISPOTS/300,000 PBMCs 65 (918.5–130.5) 68 (29.5–111.5) NS
NOTE. Abs, antibodies; ECi, Vitros Immunodiagnostic Anti-HCV Assay (Ortho-Clinical Diagnostics); ELISPOT, enzyme-linked immu-
nospots; HCV, hepatitis C virus; IDU, injection drug use; IFN, interferon; IQR, interquartile range; NS, not significant; PBMCs, peripheral
blood mononuclear cells; SI, stimulation index.
a By Mann-Whitney U test. One subject was not tested for neutralizing antibodies.
b Data are shown for 6 subjects; 1 subject was not tested.
c Data are shown for 8 subjects; 1 subject was not tested.
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cell IFN- assays (figure 3A and 3B). Statistical comparisons be-
tween the nonviremic EIA-negative participants who had T cell
responses and those who did not were limited by the small num-
ber of subjects, but it may be noteworthy that all 4 subjects who
indicated that they shared needles with others during the 6
months before analysis tested positive for T cell responses, com-
pared with 12 of 24 subjects who did not share needles (P  .11)
(data not shown). In contrast to the high prevalence of T cell
responses, nAb responses were not displayed by any nonviremic
EIA-negative subject.
DISCUSSION
Despite the high prevalence of HCV exposure and the high over-
all rate of HCV persistence [2, 4, 9, 10, 23–25], it was recently
demonstrated that IDUs who have successfully cleared HCV in-
fection in the past have a reduced risk of developing viremia on
reexposure to the virus [11, 12].
Studying subjects with long-term injection drug use (dura-
tion, 10 years), we observed that nonviremic EIA-positive
IDUs demonstrated more frequent and stronger HCV-specific T
cell responses than did viremic EIA-positive IDUs. This correla-
tion held true for both proliferation and IFN- production of
HCV-specific T cells and was noted for responses to both recom-
binant HCV proteins and overlapping peptides. The greatest dif-
ference in the strength of the response between the groups was
observed in association with HCV core and NS3. The frequency
and strength of the T cell responses of these (presumably) fre-
quently reexposed IDUs were comparable to those previously
Figure 3. Characterization of hepatitis C virus (HCV)–specific T cell responses of nonviremic EIA-negative subjects. A and B, HCV-specific proliferative T cell
responses to HCV proteins were detected in 13 of 28 exposed, uninfected subjects (A), and HCV-specific interferon (IFN)-–producing T cells in response to
pools of overlapping HCV peptides were detected in 6 of 26 exposed, uninfected subjects (B). Note that IFN-–producing T cell responses were not tested for
subjects N-16 and N-17. The stimulation index (SI) in panel A denotes proliferation in the presence of antigen relative to proliferation in the absence of antigen.
Positive responses (hatched bars) were defined as responses greater than the mean stimulation index (2 SDs) of the response of healthy blood donors. C,
HCV core peptide pool; 3, HCV NS3 peptide pool; 4A, HCV NS4A peptide pool; 4B, HCV NS4A peptide pool. C, Both CD4 and CD8 T cells of exposed,
uninfected subjects produce IFN- in response to overlapping peptides. Representative data are shown. D, HCV-specific T cell lines from HLA-A2–positive,
nonviremic EIA-negative subjects lyse HLA-matched B cell lines pulsed with the HLA-A2–restricted HCV peptides NS31073–1081 CVNGVCWTV (open circles; subject
8), Core35–44 YLLPRRGPRL (filled circles; subject 8), and Core131–140 ADLMGYIPLV (hatched circles; subject 29), respectively.
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observed in subjects who had been exposed to HCV only once in
their lifetime [14, 26 –30].
In contrast to subjects with HCV-specific T cell responses,
subjects with nAbs were more frequent in the group of viremic
EIA-positive IDUs than in the group of nonviremic EIA-positive
IDUs. The high frequency of nAbs is consistent with what has
been noted in the literature, which describes the development of
such responses late in infection [21, 31, 32]. However, these an-
tibodies may be ineffective in clearing autologous virus at the
time of sampling, because of the emergence of viral escape vari-
ants [31]. The presence of nAbs in approximately one-half of the
nonviremic EIA-positive IDUs in our study differs from previ-
ous reports, which typically did not detect nAbs in patients who
had cleared HCV [21, 32–34]. Indeed, prospective studies dem-
onstrated that HCV-specific antibody titers decrease and that
these antibodies can become undetectable after spontaneous
[14, 35] and therapy-induced clearance of HCV [36]. Our results
may be attributable to the fact that the nonviremic EIA-positive
IDUs have likely been frequently reexposed to HCV because of
continuing injection drug use, whereas cohorts in published re-
ports have consisted predominantly of individuals who had sin-
gle exposures to the virus [21, 34]. These findings suggest that
continued, long-term exposure to HCV antigens is required to
maintain humoral immune response.
Nonviremic EIA-negative IDUs exposed to HCV did not dis-
play any nAb responses, but they frequently mounted T cell re-
sponses with detectable proliferation, IFN- production, and
cytotoxicity against structural and nonstructural HCV antigens.
These subjects may have either lost all HCV-specific antibodies
after clearance of a previous HCV infection [14, 33] or may have
never mounted antibody responses [37]. The presence of CD8
T cells that target HCV nonstructural sequences is evidence that
HCV RNA translation and/or replication must have occurred at
least briefly, because CD8 T cell responses against epitopes in
nonstructural proteins are either directly primed by virus-
infected cells or cross-primed by cells that have engulfed virus-
infected cells [38].
Our report on HCV-specific T cell responses in nonviremic
EIA-negative IDUs differs from that noted in a previous study,
which did not detect T cell responses in 8 IDUs who remained
HCV EIA negative during 1 year of follow-up, despite the fact
that they had injection drug use patterns associated with a high
risk for HCV transmission [39]. The different results may be
explained by differences in study populations and immunolog-
ical techniques. The published report analyzed subjects who had
recently started injecting drugs [39], and their cumulative expo-
sure to HCV was therefore lower than that of the subjects with
long-term injection drug use (duration,10 years) in our study.
Moreover, the published report was based on an in vitro T cell
expansion technique performed with vaccinia virus–infected
antigen-presenting cells [39], which is less sensitive than the ex
vivo IFN- ELISPOT technique used with overlapping HCV
peptides in our study. At the same time, it should be acknowl-
edged that the observations in our study are restricted to HCV
genotype 1, because both the antigens used for immunological
assays and the major genotype in the UHS cohort are of geno-
type 1.
Our results are consistent with the detection of HCV-specific
T cell responses by IFN- ELISPOT analysis in 20% of nonvire-
mic EIA-negative family members of HCV-viremic patients [40,
41], and they are also reminiscent of HIV-specific T cell re-
sponses in prostitutes who remained HIV-negative despite hav-
ing continued high-risk exposure [42]. In that report, a break
from sex work for 1 year was associated with a loss of HIV-
specific CD8 T cell responses and a higher risk of HIV viremia
and seroconversion [43]. These results, along with the epidemi-
ological finding that HCV-nonviremic EIA-positive IDUs have a
reduced risk of acquiring persistent infection [11, 12], suggest T
cell–mediated immunity. Indeed, when chimpanzees that have
recovered from previous HCV infection are rechallenged with
homologous or heterologous strains of HCV [44 – 46], HCV-
specific T cells are detected within 1–2 weeks, and HCV is cleared
without evident liver injury. Depletion of either CD4 [45] or
CD8 T cells [47] before rechallenge with virus abrogates pro-
tective immunity. Thus, HCV-specific T cell responses may con-
tribute to the apparent immune protection of some IDUs [11,
12]. In contrast, the highest prevalence and titer of nAbs were
found in the group of viremic EIA-positive IDUs and in a sub-
group of nonviremic EIA-positive IDUs, who were older and
who had a longer IDU history than those without nAbs. A pro-
tective role of nAb responses immediately after reexposure
should not be excluded, however, because a recent study sug-
gests that nAbs persist for very short periods (1– 6 months) after
infection [14, 33]. A prospective study has now been initiated to
further assess the temporal relationship of risk behavior to HCV-
specific T cell and nAb responses.
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